0JV0 Stock Overview
A preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
iBio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.51 |
| 52 Week High | US$46.76 |
| 52 Week Low | US$3.51 |
| Beta | -3.84 |
| 11 Month Change | 0% |
| 3 Month Change | -0.17% |
| 1 Year Change | -84.45% |
| 33 Year Change | -99.54% |
| 5 Year Change | -99.05% |
| Change since IPO | -99.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0JV0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | 0.8% |
| 1Y | -84.4% | -16.9% | 9.1% |
Return vs Industry: 0JV0 underperformed the German Biotechs industry which returned -23.5% over the past year.
Return vs Market: 0JV0 underperformed the German Market which returned 1% over the past year.
Price Volatility
| 0JV0 volatility | |
|---|---|
| 0JV0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0JV0's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0JV0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 26 | Martin Brenner | ibioinc.com |
iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever.
iBio, Inc. Fundamentals Summary
| 0JV0 fundamental statistics | |
|---|---|
| Market cap | €3.82m |
| Earnings (TTM) | -€19.13m |
| Revenue (TTM) | €46.06k |
82.9x
P/S Ratio-0.2x
P/E RatioIs 0JV0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0JV0 income statement (TTM) | |
|---|---|
| Revenue | US$50.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$50.00k |
| Other Expenses | US$20.82m |
| Earnings | -US$20.77m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.96 |
| Gross Margin | 100.00% |
| Net Profit Margin | -41,546.00% |
| Debt/Equity Ratio | 142.8% |
How did 0JV0 perform over the long term?
See historical performance and comparison